oteseconazole + flucytosine

Oteseconazole + flucytosine is an investigational all-oral antifungal combination regimen currently being evaluated for the treatment of cryptococcal meningitis in adults living with HIV. Oteseconazole is a novel, highly selective small molecule inhibitor of fungal CYP51 (lanosterol 14-alpha demethylase), which prevents the synthesis of ergosterol, a vital component of fungal cell membranes. Flucytosine is a pyrimidine antimetabolite that is converted intracellularly to 5-fluorouracil, leading to the inhibition of fungal RNA and DNA synthesis. This combination is being studied in a Phase 2/3 platform trial (NCT06666322) sponsored by the University of Minnesota as a potential alternative to current standard-of-care induction therapies, which often involve intravenous amphotericin B and carry significant toxicity and logistical challenges in resource-limited settings.

Other names

oteseconazole and flucytosineoteseconazole/flucytosine